EHA 2018: The Issue of Frailty in MM
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.
The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.
One in four people leave their job within a year of returning to work after having a heart attack, according to a study from Denmark in the Journal… read more.
As a community IBD professionals are well aware of the need to raise the bar in terms of delivering quality care that maintains tight disease control and anticipates… read more.
Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.
Author: Gary Finnegan A ‘brain training’ game developed by researchers at the University of Cambridge, UK, could help improve the memory of patients in the very earliest stages… read more.
Men who have received initial treatment for prostate cancer with abiraterone added to hormone therapy achieved a survival rate 37 per cent higher than those not treated with… read more.
By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.
By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.
By Bruce Sylvester Diet supplementation with vitamin D3 and calcium does not appear to significantly lower risk of cancer in healthy postmenopausal women, researchers reported on March 28,… read more.